In TRUE-AHF, infusion of ularitide within 12 hours after clinical evaluation failed to improve clinical endpoints.
In patients with heart failure (HF), hospitalization is associated with accelerated disease progression, and no therapy for acute decompensated HF has proven effective at improving outcomes. Episodes of acute HF are characterized by evidence of left ventricular wall stress and myocardial injury, which might be attenuated by rapid decongestion. In a manufacturer-sponsored, double-blind, randomized, placebo-controlled trial, investigators assessed the effects of ularitide, a synthetic vasodilator, continuously infused for 48 hours beginning as soon as possible in 2157 patients hospitalized with acute decompensated HF (mean age, 68; 66% men).
Participants had persistent dyspnea at rest for ≥2 hours after intravenous diuretic treatment and a sys…
Reviewing Author
DisclosuresConsultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research
Grant/Research SupportNational Heart, Lung, and Blood Institute
Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)
Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)
DisclosuresConsultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research
Grant/Research SupportNational Heart, Lung, and Blood Institute
Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)
Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)